2nd Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.
Clin Chem Lab Med. 2011 Feb;49(2):177-84. doi: 10.1515/CCLM.2011.037. Epub 2010 Nov 18.
Ischemia modified albumin (IMA), as measured using the albumin cobalt binding test, is currently the most promising biomarker for early detection of ischemia before the onset of irreversible cardiac injury. This paper reviews the information available on IMA, including its pathophysiology, analysis, clinical applications and future perspectives. The data provided was identified by a search of MEDLINE using the terms IMA, biomarkers and ischemia. IMA may be useful to cover the complete diagnostic window of patients presenting with acute coronary syndromes (ACS) in the Emergency Department, along with the electrocardiogram and cardiac troponins. Preliminary data regarding the significance of IMA in the prognosis of either ACS or following revascularization need further study.
缺血修饰白蛋白（IMA），通过白蛋白钴结合试验进行测量，目前是在不可逆性心肌损伤发生之前早期检测缺血的最有前途的生物标志物。本文综述了 IMA 的相关信息，包括其病理生理学、分析、临床应用和未来展望。使用 IMA、生物标志物和缺血等术语在 MEDLINE 中进行检索，以确定提供的数据。IMA 可能有助于覆盖在急诊科出现急性冠状动脉综合征（ACS）的患者的完整诊断窗口期，与心电图和心肌肌钙蛋白一起使用。关于 IMA 在 ACS 预后或血运重建后的意义的初步数据需要进一步研究。
